#+TITLE: Sphingolipid Degradation: GM1/2 Gangliosidosis
#+AUTHOR: Matthew Henderson, PhD, FCACB
#+DATE: \today


* Introduction
** GM1 Gangliosidosis
- Defect in \beta-gangliosidase
- GM1 ganglioside accumulates in the brain and visera
- Infantile, juvenile and adult forms
  - Residual enzyme function
  - Devastating degenerative disease
- GM1 gangliosidosis of all types is estimated to occur in 1:100,000 - 300,000

*** MPS IVB - Morquio B
- Clinically indistinguishable from MPS IVA
  - skeletal changes, including short stature and skeletal dysplasia.
  - normal intelligence
- The prevalence of MPS IVB has been reported as 1:250,000 - 1,000,000

#+CAPTION[]: \beta-galactosidase
#+NAME: fig:bgal
#+ATTR_LaTeX: :width 0.7\textwidth
[[file:./GM1_2/figures/bgalatosidase.png]]


** Lysosomal multi-enzyme complex

- \beta-galactosidase forms a heterotrimeric complex with:
  - cathepsin A/PPCA : CTSA 
  - neuraminidase: NEU1

- \downarrow cathepsin A \to 2\degree  deficiency of NEU1
  - ML-1 (sialidosis)

#+CAPTION[lysosomal multi-enzyme complex]: Schematic representation of the pathways that involve the components
  of the LMC and the CSER, and that become deregulated in case of
  single or combined enzyme deficiencies in sialidosis, GM1 and
  GS. CMA, chaperone mediated autophagy; CSER, cell surface elastin
  receptor; EBP, elastin binding protein; ECM, extracellular matrix;
  LM, lysosomal membrane; LMC, lysosomal multienzyme complex; PM,
  plasma membrane
#+NAME: fig:lmc
#+ATTR_LaTeX: :width \textwidth
[[file:./GM1_2/figures/lmc.jpg]]

** GM2 Gangliosidosis
- Three genetic and biochemical subtypes
  - Tay-Sachs disease
  - Sandhoff disease
  - GM2 activator deficiency
- Impaired lysosomal catabolism of GM2 ganglioside.
- GM2 storage in neurons in Tay-Sachs and Sandhoff
  - Sandhoff \uparrow asialo-GM2 in brain, globoside and oligosacarides in viseral organs
- Progressive cerebral degeneration
- Prior to population-based carrier screening the incidence of TSD was ~1:3600 Ashkenazi Jewish births.
  - Incidence of TSD in the Ashkenazi Jewish population in North America \downarrow > 90%
- Eastern Quebec founder mutation


#+CAPTION[]:GM2 ganglioside storage diseases
#+NAME: tab:gm2
| Disorder                     | Onset       | Death (y) | Enzyme    |
|------------------------------+-------------+-----------+-----------|
| Tay-Sachs disease            | 3-6 months  |       2-4 | Hex A     |
| Sandhoff disease             | 3-6 months  |       2-4 | Hex A&B   |
| AB variant                   | 3-6 months  |           | Activator |
| Juvenile GM 2 gangliosidosis | 2-6 years   |      5-15 | Hex A     |
| Adult GM 2 gangliosidosis    | 2 yrs-adult |  Variable | Hex A     |


** Lysosomal \beta-Hexosaminidase enzymes

- Functional lysosomal \beta-hexosaminidase enzymes are dimeric.
- Three isozymes are produced through the combination of \alpha
  and \beta subunits
- \beta-galactosidase, hexoaminidase A and B require the M6P-receptor
- GM2 activator protein - sortilin

| Isozyme | Dimer composition | Function                                   |
|---------+-------------------+--------------------------------------------|
| A       | \alpha/\beta      | hydrolyzes GM2 ganglioside                 |
| B       | \beta/\beta       | non-GM2 gangliosides w terminal hexosamine |
| S       | \alpha/\alpha     | no known physiological function            |

#+CAPTION[]:Hexosaminidase A: Tay-Sachs
#+NAME: fig:hexa
#+ATTR_LaTeX: :width 0.8\textwidth
[[file:./GM1_2/figures/hexosaminidasea.png]]


#+CAPTION[]:Hexosaminidase A & B:Sandhoff disease
#+NAME: fig:hexb
#+ATTR_LaTeX: :width 0.8\textwidth
[[file:./GM1_2/figures/hexosaminidaseab.png]]



** Genetics
*** GM1
- GLB1: autosomal recessive 
- ~ 150 mutations in GLB1 have been described
- Neither the type or location correlate with phenotype

*** GM2
- HEXA, HEXB and GM2A: autosomal recessive
- > 130 mutations in HEXA
  - > 3 alleles comprise ~95% of Askenazi Jewish disease alleles
  - Good correlation with phenotype 
- > 40 mutations in HEXB
- 6 in GM2A

* Clinical Findings

#+CAPTION[ GM1 Signs and Symptoms]: GM1 Signs and Symptoms
#+NAME: tab:gm1ss
| Finding                | Infantile | Juvenile   | Adult            | MPS IVB                |
|------------------------+-----------+------------+------------------+------------------------|
| Onset of symptoms      | <1 year   | 1-10 years | 10+ years        | 3-5 years              |
| Eye findings           | CRS       | CC         | +/– CC           | CC                     |
| Motor abnormalities    | +         | +          | Extrapyramidal   | [fn:2]                 |
| Hepatosplenomegaly     | +         | +/–        | –                | –                      |
| Cardiac involvement    | +/–       | +/–        | +/–              | +                      |
| Coarse facial features | +/–       | –          | –                | [fn:2]                 |
| Skeletal findings      | +         | +/–        | –                | +                      |
| Neuroimaging           | PA        | PA         | +/– mild atrophy | [fn:2]                 |
| Urine (GAG)            | [fn:1]    | [fn:1]     | [fn:1]           | Keratan sulfate [fn:3] |

[fn:1] Oligosacaride with terminal galactose
[fn:2] Secondary to bony changes
[fn:3] FN have been observed


#+CAPTION[]:GM2 Signs and Symptoms
#+NAME: tab:gm2ss
| Finding           | Infantile         | Juvenile           | Adult            |
|-------------------+-------------------+--------------------+------------------|
| Onset of symptoms | <1 year           | 2-10 years         | 10+ years        |
| Eye findings      | CRS, blindness    | +/- CRS            |                  |
| movement          | weakness          | ataxia, dysarthria | dystonia, ataxia |
| Neurological      | startle response, | seizures           | psychosis        |
|                   | seizures          |                    |                  |

* Laboratory Investigations

** GM1 

- Urine oligosacarides
- Mucopolysacarides: \uparrow keratin sulfate
- /in vitro/ \beta-galactosidase activity: leukocytes and DBS
  - 4-MU-\beta-d-galactopyranoside

** GM2 
- Urine oligosacarides
- /in vitro/ Hexoaminidase activity: leukocytes, fibroblasts, ?*serum*?
  - 4-MU-6-sulfo-\beta-glucosaminide
  - specific for the \alpha subunit
- ?Heat inactivation enzyme assay?
  - \uparrow in Sandoff
  - normal in GM2 activator deficiency

- ?Falsely normal results in Tay-Sachs female carriers?

* Treatment
#+CAPTION[]:Carrier Screening for Tay-Sachs (1972-1992)
#+NAME: tab:carrier
| Group                  | number                        |
|------------------------+-------------------------------|
| Total screened         | 9.53 x 10^6 (seven countries) |
| Carriers identified    | 36 418                        |
| Couples at risk        | 1056                          |
| Pregnancies monitored  | 2415 [fn:1]                  |
| Affected fetuses       | 469                           |
| Aborted                | 451                           |
| Normal offspring born  | 1881                          |
| Birth/year w Tay-Sachs |                               |
| Prior to 1969          | 100 (US & Canada) 80% Jewish  |
| 1980                   | 13 80% non-Jewish             |
| 1985–1992              | 3-10 80% non-Jewish           |

- > 90% reduction in the disease in Jewish population

[fn:1] Prior offspring as well as heterozygote screening (1969-1992)

** GM1
- no curative treatment to date
** GM2
- treat seizures
- no curative treatment to date


